Αρχική World News Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients...

Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients With STS

Treatment of elderly patients with soft tissue sarcoma (STS) is challenging with a need to take into account comorbidities and vulnerability to medical treatments. Doxorubicin is a standard of care in patients with advanced, inoperable STS. In the EPAZ study, the German researchers tested whether pazopanib has comparable efficacy in first-line treatment of elderly patients with STS and offers better tolerability to doxorubicin. Viktor Grünwald of the Medical School Hannover and University Hospital Essen and colleagues reported on 24 August 2020 in the Journal of Clinical Oncology that pazopanib demonstrated non-inferior efficacy to doxorubicin in first-line treatment of fit elderly patients with STS with improvement in treatment-related myelotoxicity. It also had advantage in adverse events (AEs) profile, such as alopecia, stomatitis, and mucosal inflammation.

Approximately 40% of patients with STS are age 65 years or older. A retrospective analysis in elderly patients indicated that age 80 years or older, ECOG performance status of 2 or higher, and a large number of metastatic sites were associated with poor median overall survival (OS) and indicated that younger and fitter patients were more likely to receive systemic therapy in clinical practice. Furthermore, only low percentage of patients age 65 years or older are included in clinical trials.

Treatment with doxorubicin, drug predominantly used in systemic therapy for advanced or metastatic STS is associated with AEs such as neutropenia and febrile neutropenia. Given the vulnerability of geriatric patients, chemotherapy endangers this patient population and, as a consequence, hospitalisation is frequently required. Pazopanib is a tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor. It is associated with limited haematologic toxicity and has a global health status comparable to that of placebo. It is the standard of care in advanced and metastatic STS after failure of treatment with anthracyclines.

The study team assumed that the lack of severe haematologic toxicity renders pazopanib a suitable candidate for first-line treatment in elderly patients with STS, thus minimising the risk of febrile neutropenia. They designed the EPAZ trial to test whether pazopanib is not inferior to doxorubicin in patients with STS who are age 60 years or older, while offering a better risk-benefit ratio for neutropenia and febrile neutropenia. Treatment naïve patients with ECOG performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m2 once every 3 weeks for 6 cycles after being randomly assigned in a 2:1 ratio.

Non-inferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary endpoints. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient reported outcomes.

Pazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). The PFS was not inferior (HR, 1.00; 95% CI, 0.65 to 1.53). The incidence of grade 4 neutropenia and febrile neutropenia favoured pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. The OS did not differ significantly between arms.

Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients.

The authors concluded that pazopanib is not inferior in terms of efficacy compared with doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. There was superiority with pazopanib in terms of neutropenia and febrile neutropenia in elderly patients with STS. Overall incidence of toxicity remained similar for both treatments, but there were differences in the AE profiles that may help tailoring treatment to individual needs in this population.

The authors underlined that the currently predominantly fit elderly patients are selected to participate in the clinical trials. Future studies should focus on frail patients determined by geriatric assessment to develop a therapeutic strategy for this vulnerable patient population. 

Reference

Grünwald V, Karch A, Schuler M, et al. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. JCO; Published online 24 August 2020. DOI: http://ascopubs.org/doi/full/10.1200/JCO.20.00714

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

Easy Meals at Home

Our theme this week is delicious, easy to make, at home meals. These recipes minimize your cook time and maximize your food enjoyment. Ingredients 8...

This Saturday: National Prescription Drug Take-Back Day

Have you taken a look at your medicine cabinet lately? Aside from cotton swabs, mouthwash and makeup remover, are there old, outdated prescription drugs...

How People With Cancer Can Benefit From Online Therapy

Tanya J. Peterson, MS, is credentialed with the National Board of Certified Counselors. She is a regular contributor to the mental health website, Choosing...

EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

New Treatment Helps Survivors Regain Sensation After Breast Cancer

When NBC’s Kristen Dahlgren was diagnosed with breast cancer, she didn’t think much about the lack of sensation that her mastectomy would likely leave...